Safety and Efficacy of Ferric Carboxymaltose in Anemic Pregnant Women: A Retrospective Case Control Study
Table 2
Treatment characteristics of the case group () treated with FCM.
Treatment characteristics
Hb at 1st FCM treatment, g/dL ()†
8.4 7.7; 8.9]
Hb at 1st FCM treatment, mmol/L ()†
5.2 4.8; 5.5]
MCV at 1st FCM treatment, fL ()†
69 62; 76]
Gestational age at 1st treatment, weeks ()‡
34 + 6 32; 36 + 4]
Gestational age at 2nd treatment, weeks ()‡
35 + 2 32 + 6; 37 + 3]
Gestational age at 3rd treatment, weeks ()‡
32 N/E]
Total dose received, mg
1000 1000; 1500]
Treatment-related adverse outcomes reported
0 (0%)
Treatment-related serious adverse outcomes
0 (0%)
Data shown as median IQR] or (%); †patients with available data (for remainder of study population not reported); ‡total number of patients receiving treatment; Hb: hemoglobin; MCV: mean corpuscular volume; IQR: interquartile range.